Last reviewed · How we verify
NCT03306368: YORS
Youth Opioid Recovery Support: A Developmentally-specific Intervention for Home Delivery of Extended Release Naltrexone
NA trial testing Youth Opioid Recovery Support in Opioid-Related Disorders in 40 participants. Completed in 1 December 2019.
1 June 2019
Quick facts
| Lead sponsor | Potomac Health Foundations |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 February 2018 |
| Primary completion | 1 June 2019 |
| Estimated completion | 1 December 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Youth Opioid Recovery Support
Conditions studied
- Opioid-Related Disorders — all drugs for Opioid-Related Disorders →
Sponsor
Potomac Health Foundations
Who can join
Adults 18 to 26, any sex, with Opioid-Related Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Opioid addiction among youth (including both adolescents and young adults) is a growing health problem with catastrophic consequences for young people and their families. The current opioid epidemic disproportionately affects youth. Furthermore, compared to adults, adolescents and young adults tend to have poorer engagement in and response to treatment than older adults. Relapse prevention medications are the clear standard of care for the treatment of opioid addiction in adults, but the evidence base for effectiveness including implementation is not well-established in youth, and concerns from the field emphasize poor adherence and retention. Further there is no consensus regarding models of care, psychosocial treatments and platforms for delivery of medications. Extended release naltrexone (XR-NTX) has proven effectiveness in adults and is a promising pharmacotherapy for youth, but the field needs further clarification of its optimal use and delivery in this target population, in the context of developmentally informed models of care. There is inadequate current capacity for specialty opioid specific treatment that integrates pharmacotherapy (relapse prevention medication) with psychosocial treatment in a context that is youth welcoming and family empowering.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03306368
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Opioid-Related Disorders
Currently open trials in the same condition.
- NCT06810076 — Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care · NA · active not recruiting
- NCT06454903 — Developing a Smartphone Application to Support Veteran Opioid Use Disorder Treatment · NA · recruiting
- NCT06387290 — Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits · Phase 3 · recruiting
- NCT06023459 — Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR) · Phase 3 · active not recruiting
- NCT06001749 — Psilocybin in Cancer Pain Study · Phase 2 · recruiting
Other Potomac Health Foundations trials
Trials by the same sponsor.
- NCT07108608 — Adaptation of Written Exposure Therapy in Substance Treatment · NA · not yet recruiting
- NCT06774248 — Expanding the Youth Opioid Recovery Support (YORS) Intervention for MOUD Adherence to Adolescents With OUD · NA · recruiting
- NCT06696157 — EXPANDED SCOPE for Parent Grant Entitled, "Peer Recovery Support Services for Individuals in Recovery Residences on MOUD · NA · recruiting
- NCT05616949 — Peer Recovery Support Services for Individuals in Recovery Residences on MOUD · NA · active not recruiting
- NCT06296940 — Written Exposure in Substance Treatment · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03306368 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Potomac Health Foundations
- Last refreshed: 23 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03306368.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing